Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Achaogen initiated with a Buy at Stifel; tgt $27 — CREating longer-term upside (17.46)Stifel initiates AKAO with a Buy and price target of $27 as they believe plazomicin represents a revival for aminoglycosides — an antibiotic class once considered a backbone of gram-negative therapy which has been rendered increasingly ineffective against multi-drug resistant (MDR) pathogens due to widespread resistance. They also believe recently announced EPIC and CARE data provide a clear regulatory path forward and establish wholly-owned plazomicin as a desperately needed treatment option in the fight against expanded spectrum beta-lactamase (ESBL) producing and carbapenem-resistant Enterobacteriaceae (CRE), respectively. <strong>Firm believes current valuation fails to reflect what they expect to be a disconnect from historical antibiotic launch trajectories and longer-term optionality on the legislative/strategic/pipeline fronts.</strong></td> </tr></table>"